Cost-effectiveness of prostate cancer screening with multiparametric magnetic resonance imaging in the Brazilian Unified Health System
Clinical Oncology Letters · 2026 · 6 · e2026005
DOI: 10.4322/col.2026.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Oncology Letters, 2026. Verfasst von Isabela Sosnitzki Eleutério Rosa und 3 weiteren Autor:innen.
Abstract (Originalsprache)
AbptractObjectives To evaluate the cost-effectiveness of two diagnostic strategies for prostate cancer screening in men with prostate-specific antigen (PSA) ≥ 3 ng/mL from the perspective of the Brazilian Unified Health System (SUS).Methd/ps A decision-tree analytical model was developed using efficacy data from the Göteborg-2 randomized controlled trial.The compared strategies were: Strategy 1 (PSA + multiparametric MRI [mpMRI] with selective biopsy for PI-RADS 3-5 findings) and Strategy 2 (PSA + universal systematic biopsy).Direct costs were estimated from the SIGTAP/DATASUS table (2024).Effectiveness was defined as detection of clinically significant prostate cancer (ISUP grade ≥ 2).Two scenarios were analyzed: (A) mpMRI costs included in both strategies; (B) mpMRI costs excluded from Strategy 2. Mean cost, effectiveness, incremental differences, and incremental costeffectiveness ratio (ICER) were calculated.Repultps In Scenario A, Strategy 2 showed higher effectiveness (0.1732 vs. 0.1554), with an incremental cost of R$153.99 and an ICER of R$8,631.43 per additional case detected.In Scenario B, Strategy 2 was economically dominant (ICER = -R$6,530.95).The mpMRI-guided strategy reduced biopsies by 58% and overdiagnosis of ISUP 1 tumors by 50%.Sensitivity analysis confirmed the robustness of results.Cdnclupidns mpMRI improves the diagnostic efficiency of prostate cancer screening; however, its cost-effectiveness within the SUS critically depends on the technology financing model, requiring structured planning for equitable incorporation. Keywdr/ps
Zitieren
APA
Rosa, I. S. E., Sousa, L. V. D. A., Cubero, D. D. I. G., & Giglio, A. D. (2026). Cost-effectiveness of prostate cancer screening with multiparametric magnetic resonance imaging in the Brazilian Unified Health System. Clinical Oncology Letters, 6, e2026005. https://doi.org/10.4322/col.2026.005
Vancouver
Rosa ISE, Sousa LVDA, Cubero DDIG, Giglio AD. Cost-effectiveness of prostate cancer screening with multiparametric magnetic resonance imaging in the Brazilian Unified Health System. Clinical Oncology Letters. 2026;6:e2026005. doi:10.4322/col.2026.005
BibTeX
@article{Rosa2026,
author = {Rosa, Isabela Sosnitzki Eleutério and Sousa, Luiz Vinicius de Alcantara and Cubero, Daniel de Iracema Gomes and Giglio, Auro Del},
title = {Cost-effectiveness of prostate cancer screening with multiparametric magnetic resonance imaging in the Brazilian Unified Health System},
journal = {Clinical Oncology Letters},
year = {2026},
volume = {6},
pages = {e2026005},
doi = {10.4322/col.2026.005}
}
EUVIMED